Welcome to Browse Page of Biomarker

This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.

The total number entries retrieved from this search are 315
Please click on Biomarker_ID to view detailed information.
Note: Potential Biomarker with * indicates these signatures are candidate biomarkers extracted from experiments on mice, rat or cell lines and they are not validated on human patients'cohort.
Biomarker IDBiomarkerBiomoleculeSubjectRegulationBiomarker's typeExperimentLevel of significanceSourcePMID
2523MT1G, MT1FRNAsHumanDownregulated in dedifferentiated HCC (with fold change of > 0.35) Diagnosticmoderately and well differentiated HCC v/s low-differentiated HCC FDR < 5%.Tissue18820673
2524HIF1ARNAsHumanUpregulated in 17 HCC patients ( with fold change 2.14, ±0.93) and downregulated in 36 HCC patients (with fold change 0.75, ±0.26) in the HCC compared to corresponding non-malignant liver tissue PrognosticHCC v/s non-tumor; predict recurrence of HCC in patients p < 0.001Tissue20165955
2525Cytoplasmic dynein light chain, Hepatoma-derived growth factor, Ribosomal protein L6, glutathioneS-transferase, Fibronectin, Ras homolog gene family member B, TR3 orphan receptor, c-myc transcription factor (puf), MHC-class ICRNAsHumanUpregulated in HCC than non-tumorous tissue ( with average ratio more than 2) DiagnosticHCC v/s non-tumor NATissue11283847
2526Plasminogen, Corticotropin releasing hormone bindingprotein, GRO2 oncogene, Interferon gamma-inducible protein 10, alpha-Platelet-derived growth factor receptor precursor, Cell division cycle 25C, Cytochrome P450-IIC, Human intercrine-a(hIRH), IL-8RNAsHumanDownregulated in HCC than non-tumorous tissue ( with average ratio more than 2) DiagnosticHCC v/s non-tumor NATissue11283847
2527transgelin 2RNAsHumanUpregulated in HCC than non-tumorous tissue DiagnosticHCC v/s non-tumor p < 0.05Tissue15756260
2528B-factorRNAsHumanDownregulated in HCC than non-tumorous tissue DiagnosticHCC v/s non-tumor p < 0.05Tissue15756260
2529HDAC2, PSMA7, PSMD1RNAsHumanUpregulated in HCC than non-tumorous tissue DiagnosticHCC v/s non-tumor p < 0.05Tissue15756260
2530HIMAP4, C5RNAsHumanDownregulated in HCC than non-tumorous tissue DiagnosticHCC v/s non-tumor p < 0.05Tissue15756260
2531TRIM25, EIF2S3, CLECSF14, DXYS155E, T-cell receptor beta locus, GIF2H2, SPON2, VDAC2, SLC15A3, HBP1, PTPRC, FES, CDC5L, ITGB2, MPP1, NDUFA2, AHCYL1, CNP, SQLE, RPA3, LGALS1, HLA-DQA1 , STMN1, PCOLCE, LOC387680, DPT, SLK, IGBP1, SNRPG, Human-alpha1-antitrypsin gene (S variant) complete cds, SIAHBP1, RNAsHuman7 genes Downregulated i.e. CYP1A2, Human-alpha1-antitrypsin gene (S variant) complete cds, PCOLCE, CNP, DXYS155E, CLECSF14, TRIM25 and 29 get upregulated in Diagnostic and prognosticSingle nodular HCC group v/s multicentric HCC group; associated with multicentric recurrence p < 0.05Tissue16788756
2532GPC3, NCSTN, LCN2, PLK, PSK-1, PTTG1RNAsHumanUpregulated in HCC than non-tumorous tissue DiagnosticHCC v/s non-tumor p < 0.05Tissue15735714
2533PTMARNAsHumanUpregulated in mt-p53 HCC than wt-p53 HCC and non-cancerous tissue (with Fisher ratios of >2.12) Diagnosticmutant-p53 HCC v/s wild type-p53 HCC and non-cancerous tissue p < 0.01Tissue14675778
2534NUMA1RNAsHumanDownregulated in mt-p53 HCC than wt-p53 HCC ; Upregulated in wt-p53 HCC than of non-cancerous liver (with Fisher ratios of >2.12) Diagnosticmutant-p53 HCC v/s wild type-p53 HCC and non-cancerous tissue p < 0.01Tissue14675778
2535ADAR, PSMD4, D9SVA, CCT3, GBAP, RDBP, CSRP2, ILR7RNAsHumanILR-7 is Downregulated while others are Upregulated in PrognosticModerately differentiated tumor (MD) v/s Well-differentiated tumor (WD) p < 0.05Tissue12079511
2536AF147376, FLJ20084, LRP8, DKK2, AK027155, AK002039, PLSCR4, AK021998, ESDN, AKR7A2, MAP2K2, AL133075, APOL3, AK023559, GNRHR, COQ6, AF086143, FLJ14117, HUMCYT2A, D25272, M37712, KLK12, ZNF205, NM_001758, AK001102, KIAA0562, CIAO1, SRRM2, UBE1, FBXO10, AF113699, APOB, D86974, Z70704, SFRS2IP, WDFY1, RNAsHumanDiscriminating among early-stage samples (between LGDN, HGDN and G1) PrognosticDysplastic nodules of HCC v/s Edmondson grade 1 p < 0.001Tissue16175600
2537SLC38A2, AF116620, MYO1B, SULT2A1, PRRG1, FLJ14153, C8A, HSPB7, UBE2D3, AF143323, CTH, L08441, DSIPI, NYD-SP21, AFG3L1, HGD, LRP8, SDHD, ALPL, HPX, AK022053, AK027242, RFX5, GALNT10, KIAA1671, NFKBIB, LOC149832, UACA, GNG10, AL110138, AK026168, INHBA, LAMP1, MLL5, MLLT6, Z36876, BDG29, FLJ12800, ARNRNAsHumanDiscriminating among late-stage sample (between G1, G2 and G3) PrognosticEdmondson grade 1 HCC v/s Edmondson grade 2/3 HCC p < 0.001Tissue16175600
2538ILF2, BMI1, TAF9, RFX5, SSRP1, ZNF146, SREBF2, MAFG, CHD4, NR4A1, ESR1, ZNF238, FOSB, ID1, FOS, H2AFY, SNRPB, RPS7, MRPS14, HNRPU, SNRPD2, NCL, RPS10, RPL6, SFPQ, DIM1, MARS, SFRS9, RBM3, U2AF65, SFRS1, SNRPE, SF3B4, RDBP, SNRPF, RRM1, RPL38, HNRPH1, U5-116KD, RPLP1, OXA1L, ADPRT, PRKDC, SMC4L1, H2ARNAsHumanDifferentially Expressed in HCC Tumors than non-tumor (with fold change of 1.5) DiagnosticHCC v/s non-tumor p < 0.01Tissue15057898
2539NRCAM, CD24, CTHRC1, ROBO1, CENPM, FOXQ1, CDCA7L, MYBL2, PAFAH1B3, STK39, SPINK1, AKR1B10, SLC6A8, SOX4,RNAsHumanUpregulated in T3 than T1 and adjacent non-tumor (with 6 fold change) PrognosticIntrahepatic metastasis v/s primary HCC and normal p < 0.05Tissue18504433
2540SOX4RNAsHumanUpregulated in T3 than T1 and adjacent non-tumor (with 6 fold change) PrognosticIntrahepatic metastasis v/s primary HCC and normal p < 0.05Tissue18504433
2541UCP2, MSR1, HPSE, CCL2, FCER1GRNAsHumanDownregulated in HCV-HCC carcinogenesis progression PrognosticHCV-HCC v/s early HCV cirrhosis, late HCV cirrhosis, and normal liver tissues p < 0.05Tissue15108252
2542S100P, CD24, GPC3, DLK1, TM4SF3RNAsHumanUpregulated in HCV-HCC carcinogenesis progression PrognosticHCV-HCC v/s early HCV cirrhosis, late HCV cirrhosis, and normal liver tissues. p < 0.05Tissue15108252
2543TACSTD1, MYH4, PSPHL, CXCR4, N33, GMNN, MGP, RGS2, G1P2, AREG, EMP1, IFIT1, SPINK1, ADAMTS1, SLC2A3, EPHA3, GJA1, RDC1, KCNJ16, MX1, KRT23, THBD, MTHFD2, IFI44, IGF1, SGCE, SPARCL1, CYP3A5, ATP8B1RNAsHumanDownregulated in late cirrhosis than early cirrhosis (with more than 3 fold) PrognosticEarly v/s Late HCV Cirrhosis p < 0.05Tissue15108252
2544SQLE, KIAA1919, ALDH4A1, NKTR, DICER1, C1QB, CYP2A6, EIF1AY, LPA, AKR1C4, GNMT, HLA-DRB4, IGFBP2, GPR88, MBD4, DEFA1, MADH1, HFR4, KIAA1847, FTHFD, SAA1, ASS, CRP, APOF, DBY, ATF5, RPS4Y, SAA2RNAsHumanUpregulated in late cirrhosis than early cirrhosis (with more than 3 fold) PrognosticEarly v/s Late HCV Cirrhosis p < 0.05Tissue15108252
2545CDC42EP 4, IVNS1AB P, QTRT1, A2BP1, EDF1, ANXA2P3, ZNF706, STAT6, CDKN1C, DUSP6, PLOD1, ATP2A3, FAM65A, SIPA1, NCK2RNAsHumanDownregulated in HCV-Cirrhosis with HCC than HCV-cirrhosis only (with fold change more than 1.3) PrognosticHCV-Cirrhosis v/s HCV-Cirrhosis with HCC p < 0.05Tissue19098997
2546HLA-DRProtein and RNAsHumanDownregulated in HCC with early IHR vs. HCC without recurrence (with Fiser ratio 1.56) PrognosticIntrahepatic recurrence v/s Non-recurrence p < 0.05Tissue15688398
2547FBN1, MEF2C, TNFAIP3, LAPTM5, TMSB4X, CUGBP2, HLA-DRA, REL, clone110298, LTBP2, TRIM22, HLA-DRBI, FOXF1, HLA-DQA, SDF1, DDX17, SGK, PDGFRA, F2R, HLADG, MTAP44, CTSK, VIM, ACVR1, ON/SPARC, SCYA3, ARHGEF6, CCND2, COL1A1, ITGB2/CD18, PTPRC, MKNK1, JUNB, EST, GATA6, FUT3, RDBP, E48, SEMA3F, COL6A3, GBAPRNAsHuman 11 genes (FUT3, RDBP, E48, SEMA3F, COL6A3, GBAP, FUT1, GCHFR, CYP2A, MLH1, EST) Upregulated and rest 35 genes downregulated in HCC with early IHR vs. HCC without recurrence PrognosticIntrahepatic recurrence v/s Non-recurrence p < 0.05Tissue15688398
2554sterol-C5-desaturase, Peroxisomal phytanoyl-CoA alpha-hydroxylase, Homo sapiens clone 23915, Osteopontin 5/6 0, Full-length cDNA clone ZD66D02, Senescence-associated epithelial membrane protein(SEMP1), Human DNA topoisomerase II (top2) mRNA, Homo sapiens lysosomal membrane glycoprotein-2 (LAMP2), HuRNAsHumanUpregulated in HCC than non-tumor DiagnosticTumor v/s normal NATissue12136251
2555KIAA0959 protein, thymosin beta 4 Y isoform(TB4Y)mRNA, Pig7 (PIG7) mRNA, Fas binding protein (hDaxx), putative lung tumor suppressor(DAL1) mRNA complete cds, novel chemokine family member with altered, mRNA for Src-like adapter protein, OSF-1, Hu lambda-17 lambda-like protein (IGLL2), helix-loop-helRNAsHumanDownregulated in HCC than non-tumor DiagnosticTumor v/s normal NATissue12136251
2556VAMP2, ALDH3A2, DPP4, CCL3, HAPLN1, MAN2B1, RBPMS, ACSL6, ITPR2, PLEKHM2, RNF115, CIC, CALR, CENPNRNAsHumanDifferentially expressed gene Prognosticcirrhotic liver tissues with and without hepatocellular carcinoma; can predict prognosis of HCC p < 0.01Tissue19861515
2557DPP4, CALRRNAsHumanDifferentially expressed gene Prognosticcirrhotic liver tissues with and without hepatocellular carcinoma; can predict prognosis of HCC p < 0.01Tissue19861515
2558DPP4, VAMP2, EGR1RNAsHumanDifferentially expressed gene Prognosticcirrhotic liver tissues with and without hepatocellular carcinoma; can predict prognosis of HCC p < 0.01Tissue19861515
2559IL1A,IL1B,IL2,IL12A,IL12B,IL15,IFNG,TNF,IL4,IL5,IL8,IL10,CSF1,ANXA1,HLA-DRA,HLA-DPA1,PRG1RNAsHumanDiffrentially expressed between MIM (metastasis-inclined microenvironment) v/s MAM (metastasis-averse microenvironment ) PrognosticMIM (metastasis-inclined microenvironment) v/s MAM (metastasis-averse microenvironment ) p < 0.05Tissue16904609
2560IL1A,IL1B,IL2,IL12A,IL12B,IL15,IFNG,TNF,IL4,IL5,IL8,IL10,CSF1,ANXA1,HLA-DRA,HLA-DPA1,PRG1RNAsHumanDiffrentially expressed between MIM (metastasis-inclined microenvironment) v/s MAM (metastasis-averse microenvironment ) PrognosticRecurrence v/s non-recurrence p < 0.05Tissue16904609
2562galectin-3,serine/threonine kinase, translation factor eIF- 4A, -4B, -3, fibroblast growth factor receptor, and ri- bosomal protein L35ARNAsHumanUpregulated in HCC DiagnosticHCC v/s non-tumor Tissue12521301
2563Nip3, decorin, and the insulin-like growth factor binding protein-3RNAsHumanDownregulated in HCC DiagnosticHCC v/s non-tumor Tissue12521301
2564EFNA1Protein and RNAsHumanUpregulated in HCC Diagnostic and PrognosticHCC v/s non-tumor/normal; associated with the poor survival of patients p< 0.001Tissue and Seum19642143
2565EphA2Protein and RNAsHumanDownregulated in HCC Diagnostic and PrognosticHCC v/s non-tumor/normal; associated with the poor survival of patients p < 0.05Tissue and Seum19642143
2566Matrixmetalloproteinase14 or MMP14, MT-MMP1,osteonectin/SPARCRNAsHumanUpregulated in all three tested HCC samples. Diagnostic HCC v/s non-tumor p < 0.05Tissue11813304
2567Cu/Zn-SODRNAsHumanDownregulated in all three tested HCC samples. Diagnostic HCC v/s non-tumor p < 0.07Tissue11813304
2568VIM or VimentinRNAsHumanUpegulated in HCC PrognosticPrimary v/s metastasis; significantly associated with HCC metastasis p< 0.01Tissue14647434
2569H19 and IGF2RNAsHumanUpregulated in B-type HCC DiagnosticHBV-HCC vs HCV -HCC; associated with the progression of HCC p < 0.05Tissue12124323
2570MAP2K4, MAP2K5, SF1, SIAHBP1, and MYOGRNAsHumanUpregulated in B-type HCC DiagnosticHBV-HCC vs HCV -HCC; associated with the progression of HCC P< 0.05Tissue12124323
2571MMP9 and VEGFRNAsHumanUpregulated in B-type HCC DiagnosticHBV-HCC vs HCV -HCC; associated with the progression of HCC P< 0.05Tissue12124323
2572MT1E, MT1H, ADH1B, ADH4, CYP2A7, andCYPIIERNAsHumanUpregulated in C-type HCC DiagnosticHBV-HCC vs HCV -HCC; associated with the progression of HCC P< 0.05Tissue12124323
2573BMP4, FLNB, GNG11, GFR, and PTPRKRNAsHumanUpregulated in HBV-HCCs from patients with LC DiagnosticHBV-HCCs patients with LC (liver cirrhosis) vs without LC (liver cirrhosis) P< 0.05Tissue12771952
2574NFIB,GFI1,TAF1,ONECUT1,BTF,andTRIM32RNAsHumanUpregulated in HBV-HCCs from patients with LC DiagnosticHBV-HCCs patients with LC (liver cirrhosis) vs without LC (liver cirrhosis) P< 0.05Tissue12771952
2575APOC1, APOC2, andAPOC3RNAsHumanUpregulated in HBV-HCCs from patients with LC DiagnosticHBV-HCCs patients with LC (liver cirrhosis) vs without LC (liver cirrhosis) P< 0.05Tissue12771952
2576IGF2RNAsHumanUpregulated in HBV-HCCs from patients with LC DiagnosticHBV-HCCs patients with LC (liver cirrhosis) vs without LC (liver cirrhosis) P< 0.05Tissue12771952
2577PHBRNAsHumanDownregulated in HBV-HCCs from patients with LC DiagnosticHBV-HCCs patients with LC (liver cirrhosis) vs without LC (liver cirrhosis) P< 0.05Tissue12771952
2578IGFBP3RNAsHumanDownregulated in HBV-HCCs from patients with LC DiagnosticHBV-HCCs patients with LC (liver cirrhosis) vs without LC (liver cirrhosis) P< 0.05Tissue12771952
2579HSPA1BRNAsHumanDownregulated in HBV-HCCs from patients with LC than HBV-HCCs without LC DiagnosticHBV-HCCs patients with LC (liver cirrhosis) vs without LC (liver cirrhosis) P< 0.05Tissue12771952

         Raghava's group    CancerCSP    CancerSPP    CancerPDF    CancerTSP    CancerLSP    HCCPred   

Scroll to Top